UBS Maintains Buy on GRAIL, Raises Price Target to $175
10/2/2026
Impact: 90
Healthcare
UBS analyst Doug Schenkel has maintained a Buy rating on GRAIL (NASDAQ: GRAL) and increased the price target from $105 to $175. This adjustment reflects a positive outlook on the company's performance.
AI summary, not financial advice
Share: